← Back
Data updated: Jul 17, 2026
BEL MAR
Generics Pharmaceuticals
BEL MAR is a generic drug manufacturer with 18 FDA-approved products.
1958
Since
18
Drugs
-
Trials
0
New Drugs (2yr)
BEL MAR's Key Drugs
BEL MAR's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
BEL MAR's Recent FDA Approvals
New NDA/BLA approvals for BEL MAR over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
BEL MAR's Therapeutic Areas
Disease areas where BEL MAR has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
BEL MAR Pipeline Snapshot
Active clinical trials for BEL MAR across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1958-07-14
- Latest
- 1981-05-01
- Applications
- 26